Who are Peg-IFN + WB RBV for 48 weeks's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Peg-IFN + WB RBV for 16 weeks, Pegintron + Riba, B: Peg-interferon alpha-2a & Ribavirin, Peg-IFN + RBV, pegylated IFN alfa-2b plus ribavirin, pegylated interferon alpha 2a, ribavirin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/peg-ifn-wb-rbv-for-48-weeks.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Peg-IFN + WB RBV for 48 weeks — Competitive Intelligence Brief

Peg-IFN + WB RBV for 48 weeks (Peg-IFN + WB RBV for 48 weeks) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral combination therapy. Area: Infectious Disease / Virology.

marketed Antiviral combination therapy Interferon-alpha receptor; HCV RNA polymerase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Peg-IFN + WB RBV for 48 weeks (Peg-IFN + WB RBV for 48 weeks) — National Taiwan University Hospital. Pegylated interferon alpha combined with weight-based ribavirin stimulates the immune system to clear hepatitis C virus infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Peg-IFN + WB RBV for 48 weeks TARGET	Peg-IFN + WB RBV for 48 weeks	National Taiwan University Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor; HCV RNA polymerase
Peg-IFN + WB RBV for 16 weeks	Peg-IFN + WB RBV for 16 weeks	National Taiwan University Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor; HCV RNA polymerase
Pegintron + Riba	Pegintron + Riba	Chang Gung Memorial Hospital	marketed	Antiviral combination therapy (interferon + nucleoside analog)	Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase
B: Peg-interferon alpha-2a & Ribavirin	B: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); Hepatitis C virus RNA-dependent RNA polymerase
Peg-IFN + RBV	Peg-IFN + RBV	National Taiwan University Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
pegylated IFN alfa-2b plus ribavirin	pegylated IFN alfa-2b plus ribavirin	National Taiwan University Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); hepatitis C virus RNA-dependent RNA polymerase
pegylated interferon alpha 2a, ribavirin	pegylated interferon alpha 2a, ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral combination therapy class)

Kaohsiung Medical University Chung-Ho Memorial Hospital · 6 drugs in this class
National Taiwan University Hospital · 6 drugs in this class
Casa Sollievo della Sofferenza IRCCS · 1 drug in this class
Hepatitis Resource Network · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class
MTI Medical Private Limited, Pakistan · 1 drug in this class
Pacific Health Foundation · 1 drug in this class
RedHill Biopharma Limited · 1 drug in this class
Sherief Abd-Elsalam · 1 drug in this class
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Peg-IFN + WB RBV for 48 weeks — Competitive Intelligence Brief. https://druglandscape.com/ci/peg-ifn-wb-rbv-for-48-weeks. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab